Waqas Qureshi
Interventional Cardiology · Worcester, MANPI 1225267081
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Shockwave Medical, Inc at 41.5% of the total. Reporting peaked in 2024 at $8,102 and has fallen 94.6% since, to $442 in 2025.
Across 78 payments — averaging $221.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$7K
- Penumbra, Inc.$7K
- Edwards Lifesciences$2K
- Abbott$716
- Abiomed$240
- Teleflex LLC$136
- plus $485 from 6 others
Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$2K
What the payments were for
- Consulting fees$250%
- Speaking & faculty fees$10,20059%
- Travel & lodging$4,52926%
- Food & beverage$2,55915%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 5 | $7,181 |
| Penumbra, Inc. | 11 | $6,503 |
| Edwards Lifesciences | 39 | $2,052 |
| Abbott | 8 | $716 |
| Abiomed | 4 | $240 |
| Teleflex LLC | 1 | $136 |
| Medtronic(2 entities) | 2 | $126 |
| Philips North America LLC | 1 | $113 |
| Amgen | 4 | $92 |
| Boston Scientific | 1 | $88 |
| Heartflow, Inc. | 1 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,313 in reported general payments places this provider in the 70th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $45,644 |
| EntrestoSacubitril/Valsartan | 21 | $30,044 |
| JardianceEmpagliflozin | 21 | $28,597 |
| XareltoRivaroxaban | 17 | $18,751 |
| Metoprolol Succinate | 199 | $2,427 |
| Rosuvastatin Calcium | 117 | $2,361 |
| Ezetimibe | 49 | $1,590 |
| Ranolazine ErRanolazine | 14 | $1,184 |
| Amlodipine Besylate | 102 | $776 |
| ClopidogrelClopidogrel Bisulfate | 60 | $731 |
| Atorvastatin Calcium | 55 | $719 |
| Torsemide | 19 | $432 |
| Nitroglycerin | 17 | $406 |
| Lisinopril | 50 | $348 |
| Losartan Potassium | 44 | $344 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Worcester
- Vaikom MahadevanWorcester$64K
- Nikolaos KakourosWorcester$43K
- Krishna Sagar GajulaWorcester$14K
- Hafiz GhafoorWorcester$13K
- Eddison RamsaranWorcester$5K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.